AstraZeneca enlists Oracle to apply AI in drug trials
The drugmaker is using real-world data and artificial intelligence to find eligible patients and watch safety signals.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
What happened
AstraZeneca has begun a collaboration with the technology company Oracle that applies artificial intelligence and real-world data to clinical research. The work focuses on identifying patients who qualify for clinical trials and tracking safety signals during them. The partnership was announced on Tuesday, October 20.
Why it matters
Recruiting suitable patients for trials is a long-running problem in drug development, and this partnership targets it directly.
Coverage
- AZ and Oracle team up on AI platform for clinical trials (pharmaphorum.com)
- AstraZeneca partners with Oracle for AI-driven clinical trials (theedgemalaysia.com)
- AstraZeneca taps Oracle to help improve recruitment for clinical trials (fiercebiotech.com)
- AstraZeneca Partners With Oracle to Use AI in Clinical Trials (WSJ)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- Rising flu activity prompts vaccination calls in Colorado and Michigan